Piper Jaffray analyst Christopher Raymond says he's incrementally positive and would be an aggressive buyer of Inovio Pharmaceuticals (INO) this morning after an "important and overlooked data event." Inovio top-lined interim Phase 2 data looking at INO-5401 plus INO-9012 in combo with Regeneron's (REGN) Libtayo and standard of care in newly diagnosed glioblastoma multiforme, conferring six month progression free survival of 80% and 75% in methylated and un-methylated glioblastoma, respectively, Raymond tells investors in a research note. With decent patient numbers, this compares to the 60% and 40% seen in standard of care, adds the analyst. Raymond thinks this morning's update potentially portends a "real advance" in glioblastoma multiforme. With Inovio's current $236M market capitalization, the analyst sees a "sizeable disconnect" in the shares. He keeps an Overweight rating on the shares with a $10 price target. The stock in early trading is up 9%, or 21c to $2.59.